Anthony Lembo
Beth Israel Deaconess Medical Center
DefecationInternal medicineSurgeryRandomized controlled trialIntensive care medicinePhysical therapyPlaceboBloatingGERDIrritable bowel syndromeRifaximinDiarrheaLinaclotideAbdominal painConstipationChronic constipationIn patientClinical trialMedicineGastroenterology
396Publications
71H-index
13.6kCitations
Publications 398
Newest
#1Catherine P. Gardiner (BIDMC: Beth Israel Deaconess Medical Center)
#2Prashant Singh (UM: University of Michigan)H-Index: 8
Last. Johanna Iturrino (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
view all 8 authors...
BACKGROUND Abdominal bloating is common in functional gastrointestinal disorders (FGID). To better characterize this patient population, we evaluated clinical and psychological characteristics of bloating and analyzed their differences by bloating severity. METHODS Patients with FGIDs evaluated at a single academic outpatient referral gastroenterology clinic were surveyed. Bloating severity was classified as minimal, moderate or severe. Symptom-specific questionnaires were used to evaluate bowel...
Source
#1Eric D. Shah (Dartmouth College)H-Index: 8
#2Kyle Staller (Harvard University)H-Index: 13
Last. William D. CheyH-Index: 78
view all 9 authors...
INTRODUCTION Chronic idiopathic constipation (CIC) is a common and burdensome illness. We performed a cost-effectiveness analysis of the US Food and Drug Administration-approved CIC drugs to evaluate and quantify treatment preferences compared with usual care from insurer and patient perspectives. METHODS We evaluated the subset of patients with CIC and documented failure of over-the-counter (OTC) osmotic or bulk-forming laxatives. A RAND/UCLA consensus panel of 8 neurogastroenterologists inform...
Source
#1Vikram Rangan (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 10
#2Anthony Lembo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 71
1 CitationsSource
#1Prashant Singh (UM: University of Michigan)H-Index: 8
#2Sarah Ballou (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
Last. Judy Nee (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 14
view all 8 authors...
Abstract null null Background & Aims null Symptoms of functional dyspepsia (FD) fluctuate over time but there is limited data on impact of factors on change in dyspepsia symptom severity over time. We aimed to evaluate the demographic, clinical and psychological factors associated with change in dyspepsia symptom severity. null null null Methods null Consecutive patients with FD presenting to a tertiary care center completed questionnaires assessing clinical and psychological symptoms at the tim...
Source
#1Judy Nee (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 14
#2Sarah Ballou (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
Last. Johanna Iturrino (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
view all 10 authors...
INTRODUCTION Peppermint oil is often used to treat irritable bowel syndrome (IBS); however, the overall quality of previous studies is low, and findings have been heterogeneous. This study aimed to compare the effects of peppermint oil vs placebo in relieving IBS symptoms. METHODS In a 6-week, randomized, double-blind, placebo-controlled trial at a single academic center in the United States, individuals diagnosed with IBS (Rome IV criteria), with moderate to severe symptoms based on the IBS Sev...
Source
#1Prashant Singh (UM: University of Michigan)H-Index: 8
#1Prashant SinghH-Index: 58
Last. Anthony Lembo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 71
view all 2 authors...
Advances in bioinformatics have facilitated investigation of the role of gut microbiota in patients with irritable bowel syndrome (IBS). This article describes the evidence from epidemiologic and clinical observational studies highlighting the link between IBS and gut microbiome by investigating postinfection IBS, small intestinal bacterial overgrowth, and microbial dysbiosis. It highlights the effects of gut microbiota on mechanisms implicated in the pathophysiology of IBS, including gut-brain ...
Source
#1Sarah Ballou (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
#2Johanna IturrinoH-Index: 12
Last. Judy NeeH-Index: 14
view all 8 authors...
OBJECTIVES Tricyclic antidepressants (TCAs) are commonly used to treat disorders of gut-brain interaction (DGBI). However, these medications are often associated with side effects that lead to early treatment discontinuation. Research in other chronic medical conditions suggests that many TCA side effects may be caused by nocebo (negative placebo) effects. The current study tests a brief, verbal intervention aimed at improving tolerance of TCAs in DGBI by providing education about nocebo effects...
Source
#1William D. Chey (UM: University of Michigan)H-Index: 78
#2Anthony Lembo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 71
Last. David P. RosenbaumH-Index: 6
view all 4 authors...
INTRODUCTION Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the long-term efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). METHODS In this randomized double-blind study (ClinicalTrials.gov identifier: NCT02686138), patients with IBS-C received tenapanor 50 mg b.i.d. or placebo b.i.d. for 26 weeks....
3 CitationsSource
#1Vanessa Yu (BIDMC: Beth Israel Deaconess Medical Center)
#2Sarah Ballou (UM: University of Michigan)
Last. Anthony LemboH-Index: 71
view all 9 authors...
INTRODUCTION Patients with disorders of gut-brain interaction (DGBIs) are high users of health care. Past studies exploring predictors of utilization have lacked patient-level clinical data. The aim of the current study is to identify demographic, clinical, and psychological predictors of health care utilization in patients with irritable bowel syndrome (IBS), functional constipation (FC), and functional diarrhea (FDr). METHODS Consecutive new patients diagnosed with IBS, FC, and FDr (using Rome...
Source
Source